The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and tolerability of first-line abiraterone + prednisone (ABI) versus enzalutamide (ENZ) for metastatic castration-resistant prostate cancer (mCRPC) in men ≥ 80 years: A retrospective cohort study.
 
Daniel Khalaf
No Relationships to Disclose
 
Kevin Zou
No Relationships to Disclose
 
Werner J. Struss
No Relationships to Disclose
 
Bernhard J. Eigl
Honoraria - Janssen; Pfizer
Consulting or Advisory Role - AstraZeneca; Merck; Roche Canada
Speakers' Bureau - Merck
Travel, Accommodations, Expenses - AstraZeneca; Janssen
 
Christian K. Kollmannsberger
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Daygen L. Finch
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; Novartis; Pfizer
Speakers' Bureau - Pfizer
 
Krista Noonan
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Sanofi
 
Joanna Vergidis
Honoraria - Astellas Pharma; Bayer; Janssen; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Pfizer
Travel, Accommodations, Expenses - Astellas Pharma; Bayer
 
Muhammad Zulfiqar
No Relationships to Disclose
 
Kim N. Chi
Honoraria - Amgen; Astellas Pharma; Janssen; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; ESSA; Janssen; Lilly/ImClone; Sanofi
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Lilly/ImClone (Inst); Novartis (Inst); Oncogenex (Inst); Sanofi (Inst); Teva (Inst); Tokai Pharmaceuticals (Inst)